» Articles » PMID: 30586743

Hematopoietic Deficiency of the Long Noncoding RNA MALAT1 Promotes Atherosclerosis and Plaque Inflammation

Abstract

Background: The majority of the human genome comprises noncoding sequences, which are in part transcribed as long noncoding RNAs (lncRNAs). lncRNAs exhibit multiple functions, including the epigenetic control of gene expression. In this study, the effect of the lncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) on atherosclerosis was examined.

Methods: The effect of MALAT1 on atherosclerosis was determined in apolipoprotein E-deficient (Apoe) MALAT1-deficient (Malat1) mice that were fed with a high-fat diet and by studying the regulation of MALAT1 in human plaques.

Results: Apoe Malat1 mice that were fed a high-fat diet showed increased plaque size and infiltration of inflammatory CD45 cells compared with Apoe Malat1 control mice. Bone marrow transplantation of Apoe Malat1 bone marrow cells in Apoe Malat1 mice enhanced atherosclerotic lesion formation, which suggests that hematopoietic cells mediate the proatherosclerotic phenotype. Indeed, bone marrow cells isolated from Malat1 mice showed increased adhesion to endothelial cells and elevated levels of proinflammatory mediators. Moreover, myeloid cells of Malat1 mice displayed enhanced adhesion to atherosclerotic arteries in vivo. The anti-inflammatory effects of MALAT1 were attributed in part to reduction of the microRNA miR-503. MALAT1 expression was further significantly decreased in human plaques compared with normal arteries and was lower in symptomatic versus asymptomatic patients. Lower levels of MALAT1 in human plaques were associated with a worse prognosis.

Conclusions: Reduced levels of MALAT1 augment atherosclerotic lesion formation in mice and are associated with human atherosclerotic disease. The proatherosclerotic effects observed in Malat1 mice were mainly caused by enhanced accumulation of hematopoietic cells.

Citing Articles

Emerging Roles of Long Non-Coding RNAs in Cardiovascular Diseases.

Kong X, Li F, Wang Y J Cell Mol Med. 2025; 29(5):e70453.

PMID: 40032652 PMC: 11875779. DOI: 10.1111/jcmm.70453.


The role of long non-coding RNAs in cardiovascular diseases: A comprehensive review.

Xie X, Huang M, Ma S, Xin Q, Wang Y, Hu L Noncoding RNA Res. 2025; 11:158-187.

PMID: 39896344 PMC: 11783329. DOI: 10.1016/j.ncrna.2024.12.009.


New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet's disease.

Sayed N, Shaker O, Abd-Elmawla M, Gamal A, Fathy N Clin Rheumatol. 2025; 44(2):775-787.

PMID: 39798064 PMC: 11774967. DOI: 10.1007/s10067-024-07291-x.


Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells.

Zhuang B, Zhong C, Ma Y, Wang A, Quan H, Hong L Int J Mol Sci. 2025; 26(1.

PMID: 39796085 PMC: 11720039. DOI: 10.3390/ijms26010231.


The Diagnosis and Prognosis Value of Circulating Exosomal lncRNA MALAT1 and LNC_000226 in Patients With Acute Myocardial Infarction: An Observational Study.

Gu X, Hou J, Weng R, Rao J, Liu S Immun Inflamm Dis. 2024; 12(12):e70088.

PMID: 39641229 PMC: 11621859. DOI: 10.1002/iid3.70088.